Abstract
From 1 January 1999, all requests by pharmaceutical manufacturers and others to Blue Cross and Blue Shield (BCBS) of Colorado and Nevada for the listing of new pharmaceutical products or any proposed change to the formulary status of an existing product must be accompanied by a submission which meets the informational and analytical standards set out in the BCBS Guidelines for Formulary Submissions for Pharmaceutical Product Evaluation. These submission requirements relate both to the anticipated therapeutic impact of a new product and to claims made as to its anticipated pharmacoeconomic impact.
The guidelines have been developed because BCBS is concerned that decisions to admit a drug to formulary have been based in the past on incomplete information. In order to rectify this situation (and to meet quality control objectives), it has been decided that all submissions to BCBS should meet a common information standard that describes both the characteristics of the product and its expected impact in a disease or therapeutic area.
Unlike guidelines that have been introduced in countries such as Australia and the Canadian Province of Ontario, these guidelines take an explicit systems approach to the case a manufacturer must make before a product is considered for formulary listing. While the notion of systems impact requirements is not new, this is the first time that a managed healthcare system in the US has adopted this explicit perspective and notified manufacturers that traditional pharmacoeconomic evaluations may not meet the information needs of drug purchasers.
The purpose of this paper is to describe the BCBS formulary guidelines and to demonstrate how manufacturers are expected to meet the information needs of a systems impact perspective in submissions to the pharmacy and therapeutics committee.
Article PDF
Similar content being viewed by others
References
Langley PC. Blue Cross and Blue Shield of Colorado, Guidelines for formulary submissions for pharmaceutical product evaluation. Denver (CO): Blue Cross and Blue Shield, 1998
Rittenhouse B. Uses of models in economic evaluations of medicines and other health technologies. London: Office of Health Economics, 1996
Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on the preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Publishing Service, 1992
Department of Human Services and Health. Guidelines for the pharmaceutical industry on the preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Publishing Service, 1995
Ministry of Health. Ontario guidelines for the economic analysis of pharmaceuticals. Toronto (ON): Ministry of Health, 1994
Langley PC. Pharmacoeconomics: achieving gold standards. London: Financial Times Healthcare, 1997
Langley PC, Sullivan SD. Pharmacoeconomic evaluations: guidelines for drug purchasers. J Manage Care Pharm 1996; 2 (6): 671–7
Langley PC, Martin RE. Guidelines for formulary submission, October 1996. Rancho Cordova (CA): Foundation Health and Integrated Pharmaceutical Services, 1996
Langley PC, Martin RE. Managed care guidelines for the economic evaluation of pharmaceuticals. Am J Manage Care 1997; 3: 733–41
Regence Washington Health Pharmacy Services. Guidelines for the submission of clinical and economic data supporting formulary consideration. Seattle (WA): Regence Washington Health, 1997
Drummond MF, O’Brien B, Stoddart GL. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997
Feldstein PJ. Health care economics. 5th ed. Albany (NY): Delmar, 1999
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Langley, P.C. Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada. Pharmacoeconomics 16, 211–224 (1999). https://doi.org/10.2165/00019053-199916030-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199916030-00001